FAMPYRA received Health Canada approval for the symptomatic improvement of walking in adult MS patients with walking disability.
The approval of FAMPYRA was based on the results of two Phase III clinical trials, which demonstrated efficacy in people with all types of MS.
A significantly greater proportion of patients taking FAMPYRA had consistent improvement in walking speed when compared to placebo, the studies reported.
MS is often debilitating disease of the central nervous system that attacks the protective covering, or myelin, of the brain and spinal cord, causing inflammation and damage.